ACP
SRNE

Acuta Capital Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Acuta Capital Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-80,000
Closed -$925K – 63
2015
Q1 		$925K Buy
+80,000
New +$926K 0.78% 34

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acuta Capital Partners's SRNE Position: Q4 2015 in Review

Acuta Capital Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2015, closing a stake of 300,000 shares — an estimated $2.52M sold.

Acuta Capital Partners first reported a position in SRNE in Q2 2015 and held it in 2 quarters. The position peaked at $3.74M in Q2 2015. 84 funds tracked by Wall St. Rank hold SRNE as of Q4 2015.

  • Acuta Capital Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 300,000 Sorrento Therapeutics, Inc. shares in Q4 2015, an estimated $2.52M.
  • Acuta Capital Partners first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Acuta Capital Partners's Sorrento Therapeutics, Inc. position peaked at $3.74M in Q2 2015.
  • 84 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.